Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | TNF | P01375 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16114904 | 1.00 | MAPT (0.47) | MAPTKDM4ETDP1FKBP1AALDH1A1 | |
| SCHEMBL28009398 | 0.86 | MAPT (0.47) | MAPTTDP1FKBP1AALDH1A1KMT2A | |
| SCHEMBL28009407 | 0.81 | ALDH1A1 (0.44) | MAPTKDM4ETDP1FKBP1AALDH1A1 | |
| SCHEMBL10173636 | 0.79 | ALDH1A1 (0.45) | MAPTTDP1ALDH1A1KMT2ALMNA | |
| SCHEMBL7416582 | 0.78 | KDM4E (0.67) | MAPTKDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL2824161 | 0.78 | NOTUM (0.56) | KDM4EALDH1A1TP53 | |
| SCHEMBL2824164 | 0.78 | NOTUM (0.56) | KDM4EALDH1A1TP53 | |
| SCHEMBL16135452 | 0.77 | MAPT (0.51) | MAPTKDM4ETDP1ALDH1A1LMNA | |
| SCHEMBL17600352 | 0.75 | MAPT (0.43) | MAPTKDM4EFKBP1AALDH1A1KMT2A | |
| SCHEMBL16115047 | 0.75 | MAPT (0.43) | MAPTKDM4EFKBP1AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | viDA Therapeutics (CA) | 2019-06-25 | — | — | US | disclosed |
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2018-03-01 | — | — | US | disclosed |
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2018-03-01 | — | — | US | disclosed |
| US-9605021-B2 | Indoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-03-28 | — | — | US | disclosed |
| US-9605021-B2 | Indoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-03-28 | — | — | US | disclosed |
| US-9605021-B2 | Indoline compounds as granzyme B inhibitors | VIDA THERAPEUTICS INC. (CA) | 2017-03-28 | — | — | US | disclosed |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2016-03-24 | — | — | US | disclosed |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | VIDA THERAPEUTICS INC. (CA) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180057528-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | MAPT 3993/4885KDM4E 3437/4885TDP1 987/4885 |
| US-10329324-B2 | Indoline compounds as granzyme B inhibitors | GZMB, PRF1, CTSB | MAPT 3993/4885KDM4E 3437/4885TDP1 987/4885 |
| US-20160083422-A1 | INDOLINE COMPOUNDS AS GRANZYME B INHIBITORS | GZMB, PRF1, CTSB | MAPT 3993/4885KDM4E 3437/4885TDP1 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.